Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Reported total revenues of $1.65 billion, an increase of 29%
Subscribe to our email newsletter
Gilead has posted a total revenue of $1.65 billion for the second quarter of 2009, an increase of 29% compared to total revenues of $1.28 billion for the second quarter of 2008. Net income for the second quarter was $571.4 million, or $0.61 per diluted share, compared to $434.8 million, or $0.45 per diluted share during the second quarter of 2008.
Non-GAAP net income of the company (excluding after-tax acquisition-related expenses, restructuring expenses and stock-based compensation expenses) was $648.9 million, or $0.69 per diluted share, compared to $469 million, or $0.48 per diluted share for the second quarter of 2008.
Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.